دورية أكاديمية
Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database.
| العنوان: | Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database. |
|---|---|
| المؤلفون: | Yang Q; Department of Anesthesiology, Huaihe Hospital of Henan University, No. 8, Baobei Road, Gulou District, Kaifeng, 475000, China., Wang J; Department of Anaesthesiology, Laboratory of Mitochondria and Metabolism, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China., Wang M; Department of Anesthesiology, Huaihe Hospital of Henan University, No. 8, Baobei Road, Gulou District, Kaifeng, 475000, China., Zhang S; Department of Anesthesiology, Huaihe Hospital of Henan University, No. 8, Baobei Road, Gulou District, Kaifeng, 475000, China., He QQ; Department of Anaesthesiology, Laboratory of Mitochondria and Metabolism, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China. heqinqin2022@wchscu.cn. |
| المصدر: | BMC pharmacology & toxicology [BMC Pharmacol Toxicol] 2024 Sep 12; Vol. 25 (1), pp. 64. Date of Electronic Publication: 2024 Sep 12. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: BioMed Central Country of Publication: England NLM ID: 101590449 Publication Model: Electronic Cited Medium: Internet ISSN: 2050-6511 (Electronic) Linking ISSN: 20506511 NLM ISO Abbreviation: BMC Pharmacol Toxicol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : BioMed Central |
| مواضيع طبية MeSH: | Adverse Drug Reaction Reporting Systems*/statistics & numerical data , Anti-Obesity Agents*/adverse effects , Anti-Obesity Agents*/therapeutic use , United States Food and Drug Administration* , Pharmacovigilance*, Humans ; United States/epidemiology ; Male ; Female ; Adult ; Middle Aged ; Databases, Factual ; Aged ; Young Adult ; Digestive System Diseases/chemically induced ; Digestive System Diseases/epidemiology ; Obesity/epidemiology ; Liraglutide/therapeutic use ; Liraglutide/adverse effects ; Adolescent |
| مستخلص: | Background: Numerous digestive system adverse events (dsAEs) have been observed during the use of anti-obesity medications (AOMs), leading to concerns about the safety of these medications. However, most current studies are limited to the association of one class of drugs with specific digestive disorders, and there is no cascading analysis of AOMs in the digestive system. This study aims to use data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) for a stratified analysis of the reported associations between AOMs and dsAEs. Methods: We analyzed adverse event reports submitted to FAERS between January 2015 and December 2023 related to obesity treatment. It is important to note that FAERS data cannot establish causality or incidence rates. Pharmacovigilance (PV) signals were detected by disproportionate analyses through proportionate reporting ratio (PRR), reporting odds ratios (ROR), and information components (IC) to detect dsAEs associated with AOMs. Reporting rates, severity, and response outcomes of digestive adverse events were compared across AOMs by multivariate logistic regression analysis. Results: Among 34,396 adverse events (AEs) related to obesity treatment, 8844 dsAEs were analyzed. Comparing with semaglutide and liraglutide, tirzepatide exhibited fewer reported dsAEs while semaglutide and liraglutide showed a high correlation with non-lethal pancreatitis reports. Bupropion-naltrexone (31.65%) reported the highest number of dsAEs, and a PV signal was detected in mouth and lips AEs (ROR = 2.97, 95% CI: 2.42-3.6). Orlistat (ROR = 3.30, 95% CI: 3.08-3.55) exhibited the highest association with gastrointestinal AEs compared to other AOMs. PV signal for hepatobiliary AEs (ROR = 6.13, 95% CI: 3.45-10.88) with phentermine-topiramate still needs further clarification. Conclusions: Tirzepatide may be considered for patients with a history of digestive system disease or an elevated risk of pancreatitis based on the pattern of reported dsAEs. Caution is needed for the orofacial AEs when using bupropion-naltrexone. Orlistat has a higher reporting rate of gastrointestinal AEs, but these events are typically less severe. Phentermine-topiramate's association with liver impairment requires further clinical investigation. This article provides insights into the reported associations between AOMs and dsAEs, which may aid clinicians in making more informed decisions about individualizing medication and managing potential adverse events. (© 2024. The Author(s).) |
| References: | Front Endocrinol (Lausanne). 2023 Apr 21;14:1161521. (PMID: 37152942) AAPS J. 2008;10(1):35-41. (PMID: 18446503) Int J Clin Pharm. 2022 Feb;44(1):172-179. (PMID: 34564826) Curr Obes Rep. 2019 Sep;8(3):284-291. (PMID: 31124035) Obes Rev. 2022 Jun;23(6):e13435. (PMID: 35194917) N Engl J Med. 2022 Oct 13;387(15):1433. (PMID: 36239652) Clin Nutr. 2002 Oct;21(5):395-402. (PMID: 12381337) N Engl J Med. 2017 Jan 19;376(3):254-266. (PMID: 28099824) Healthcare (Basel). 2022 Feb 23;10(3):. (PMID: 35326898) Gastroenterology. 2011 Jul;141(1):150-6. (PMID: 21334333) BMJ Glob Health. 2022 Sep;7(9):. (PMID: 36130777) Lancet. 2011 Aug 27;378(9793):804-14. (PMID: 21872749) Obes Facts. 2014;7(6):408-16. (PMID: 25503968) EClinicalMedicine. 2023 Apr 21;59:101967. (PMID: 37131541) Drugs. 2015 Jul;75(11):1269-80. (PMID: 26105116) Diabetes Obes Metab. 2021 Jul;23(7):1542-1551. (PMID: 33651454) Gastroenterology. 2022 Nov;163(5):1198-1225. (PMID: 36273831) Clin Genitourin Cancer. 2023 Oct;21(5):594-601.e2. (PMID: 37482524) Expert Opin Pharmacother. 2015 Jun;16(8):1263-74. (PMID: 25958964) Lancet. 2010 Aug 21;376(9741):595-605. (PMID: 20673995) Drug Saf. 2024 Jun;47(6):585-599. (PMID: 38713347) Science. 2023 Dec 15;382(6676):1226-1227. (PMID: 38096291) Obesity (Silver Spring). 2014 Jul;22 Suppl 2:S1-3. (PMID: 24961822) Ann Intern Med. 2019 Mar 5;170(5):ITC33-ITC48. (PMID: 30831593) Obes Rev. 2023 Mar;24(3):e13543. (PMID: 36579723) PLoS One. 2016 Jul 29;11(7):e0160221. (PMID: 27472273) Ann Surg Open. 2023 Dec 04;4(4):e317. (PMID: 38144499) Obesity (Silver Spring). 2013 May;21(5):935-43. (PMID: 23408728) JAMA. 2020 Sep 1;324(9):879-887. (PMID: 32870301) Drugs. 2006;66(12):1625-56. (PMID: 16956313) Nat Rev Endocrinol. 2019 May;15(5):288-298. (PMID: 30814686) Biochem Pharmacol. 2019 Dec;170:113669. (PMID: 31628911) Life (Basel). 2020 Aug 05;10(8):. (PMID: 32764444) JAMA. 2023 Nov 14;330(18):1795-1797. (PMID: 37796527) Drug Saf. 2014 Jun;37(6):421-31. (PMID: 24743876) Lancet. 2023 Apr 1;401(10382):1116-1130. (PMID: 36774932) Lancet. 2017 Dec 16;390(10113):2627-2642. (PMID: 29029897) Diabetes Obes Metab. 2016 Mar;18(3):224-35. (PMID: 26500045) |
| فهرسة مساهمة: | Keywords: Anti-obesity medications; Digestive adverse events; Disproportionality analysis; FDA adverse event reporting system database; Obesity; Pharmacovigilance |
| المشرفين على المادة: | 0 (Anti-Obesity Agents) 839I73S42A (Liraglutide) |
| تواريخ الأحداث: | Date Created: 20240912 Date Completed: 20240913 Latest Revision: 20240915 |
| رمز التحديث: | 20240915 |
| مُعرف محوري في PubMed: | PMC11391863 |
| DOI: | 10.1186/s40360-024-00789-9 |
| PMID: | 39267168 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2050-6511 |
|---|---|
| DOI: | 10.1186/s40360-024-00789-9 |